FMP
Mind Medicine (MindMed) Inc.
MNMD
NASDAQ
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
7.16 USD
0.145 (2.03%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Robert Barrow
sector
Healthcare
industry
Biotechnology
website
https://www.mindmed.coexchange
NASDAQ
Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
CIK
0001813814
ISIN
CA60255C8850
CUSIP
60255C109
Address
1055 West Hastings Street
Phone
650 208 2454
Country
CA
Employee
57
IPO Date
Nov 15, 2016
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MNMD Financial Summary
CIK
0001813814
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
60255C109
ISIN
CA60255C8850
Country
CA
Price
7.16
Beta
2.33
Volume Avg.
1.17M
Market Cap
525.05M
Shares
-
52-Week
3.457-12.22
DCF
2.19
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.19
P/B
-
Website
https://www.mindmed.co
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MNMD News
It looks like there's no news available.
